Shares of Regulus Therapeutics Inc. (RGLS) touched a 52-week high of $3.73 during intraday trading yesterday, reflecting continued investor confidence in the company's long-term prospects, particularly its plan to advance its lead drug candidate into a pivotal program later this year.
The lead drug candidate in focus is Farabursen, a novel, next-generation oligonucleotide for the treatment of autosomal dominant polycystic kidney disease, which is a rare genetic disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com